15 August 2016
Australian men with non-metastatic castrate resistant prostate cancer and a high risk for developing metastatic disease, may be eligible to participate in a clinical trial of a new androgen receptor antagonist. ARAMIS (Androgen Receptor inhibiting Agent for MetastatIc-free Survival) is a phase 3 clinical trial examining the safety and efficacy of ODM-201 and is currently recruiting patients at several institutions in NSW, QLD and VIC. The primary objective of the trial is to determine if ODM-21 delays time to development of metastases.
If you would like further information please contact your oncologist or visit www.australianclinicaltrials.gov.au
